ClinicalTrials.gg
CompletedNCT01698905ENESTopUpdated Aug 12, 2026Results posted

Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

A Phase 2 interventional study of nilotinib in Chronic Myeloid Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 62 sites in 18 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
163
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
16th of 66
163 · median 55
Started
2012
with 5 others
Phase 2
25 of 66
1 open now
Registered
35th of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 16th largest by enrollment, is one of 6 that started in 2012, is one of 25 in phase 2, and was the 35th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

A clinical research study to find out if it is safe to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients. Patients who started treatment with imatinib (Gleevec) when they were first diagnosed with CML, then switched to nilotinib (Tasigna) for at least 2 years with the combined time on imatinib (Gleevec) and nilotinib (Tasigna) for at least 3 years and have very small amount of leukemia cells remaining after the nilotinib (Tasigna) treatment will qualify for the study.

Read the detailed description

The Primary objective was to evaluate the percentage of patients in TFR within 48 weeks following nilotinib cessation.

This study originally consisted of seven phases (five treatment phases and two treatment-free phases) from which two were the focus of this primary analysis report (consolidation, TFR and treatment re-initiation) The study consisted of 2 main phases: Consolidation and TFR

Nilotinib treatment consolidation phase (NTCS): Patients who satisfied all inclusion/exclusion criteria were enrolled in the consolidation phase and continued to receive nilotinib for 52 weeks at the dose which the patient was receiving prior to study entry. If a patient maintained MR4.5 throughout the consolidation phase, he/she was eligible to enter in the TFR phase. If a patient had confirmed loss of MR4.5 during the consolidation phase, he/she was not eligible to enter in the TFR phase and continued nilotinib treatment.

Nilotinib TFR phase: Patients who were eligible to enter in the TFR phase after completing the 52 week consolidation phase stopped taking nilotinib on the first day of the TFR phase. Duration of this phase was up to 520 weeks after the last patient enters in the TFR phase.

Nilotinib treatment re-initiation phase (NTRI): If a patient had a confirmed loss of MR4 (two consecutive BCR-ABL >0.01% IS) or loss of MMR (BCR-ABL >0.1% IS) in the TFR phase, the patient restarted nilotinib treatment. Patients will be on nilotinib treatment for up to 520 weeks after the last patient entered the nilotinib TFR phase, or until a patient experience unacceptable toxicity, disease progression and/or treatment discontinued at the discretion of the Investigator or if the patient withdrew consent. Nilotinib cessation was not attempted for a second time in the patient who reinitiated treatment or discontinued following the TFR phase.

Nilotinib treatment continuation phase (NTCT) and Nilotinib treatment prolonged continuation phase (NTCT-P): Patients who were not eligible to enter into the TFR phase after completing the 52-week NTCS phase entered the nilotinib treatment continuation (NTCT) phase and would continue treatment with nilotinib for another 52 weeks (a total of 104 weeks of treatment). Patients who were not able to maintain MR4.5 and had a confirmed loss of MR4.5 during the NTCT phase were not eligible to enter the TFR-2 phase. These patients entered into the nilotinib prolonged treatment continuation phase (NTCT-P) and continued nilotinib treatment until 520 weeks after the last patient entered the nilotinib TFR phase, or until the patients experience unacceptable toxicity, disease progression and/or treatment would be discontinued at the discretion of the Investigator or withdrawal of consent.

Nilotinib TFR-2 phase: Patients who maintained MR4.5 during the NTCT phase were eligible to cease nilotinib treatment and enter the TFR-2 phase. The duration of the nilotinib TFR-2 phase is up to 520 weeks after the last patient entered the TFR phase. Patients stopped taking nilotinib therapy on the day they entered the TFR-2 phase.

Nilotinib treatment re-initiation-2 (NTRI-2): If a patient had a loss of MMR or a confirmed loss of MR4 during the TFR-2 phase, he/she entered the nilotinib treatment re-initiation-2 (NTRI-2) phase and resumed nilotinib treatment at a dose of either 300 mg or 400 mg bid.

Safety follow-up was performed within 30 days after the last dose of study treatment or the last day in TFR/TFR-2.

Post-treatment follow-up visits were performed every 12 weeks up to 520 weeks after the last patient entered the nilotinib TFR phase.

03

Conditions studied

  • Chronic Myeloid Leukemia

Keywords

  • AMN107
  • CML
  • Phase II
  • single arm
  • open label
  • nilotinib
  • treatment-free remission
  • MR4.5
  • confirmed loss of MR4
  • loss of MMR
  • Ph+ CML-CP
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients >= 18 years of age
  2. Performance Status of 0, 1, or 2
  3. Patient with diagnosis of BCR-ABL positive CML CP
  4. Patient has received a minimum of 3 years of tyrosine kinase inhibitor treatment (first with imatinib (> 4 weeks) and then switched to nilotinib) since initial diagnosis
  5. Patient has at least 2 years of nilotinib treatment prior to study entry.
  6. Patient has achieved MR4.5 (local laboratory assessment) during nilotinib treatment, and determined by a Novartis designated central PCR lab assessment at screening
  7. Adequate end organ function as defined by:

    • Direct ≤ 1.5 x except for i) patient with documented Gilbert's syndrome for whom any bilirubin value is allowed and ii) for patients with asymptomatic hyperbilirubinemia (liver transaminases and alkaline phosphatase within normal range)
    • (AST) and SGPT(ALT) \< 3 x ULN (upper limit of normal)
    • Serum lipase ≤ 2 x ULN
    • Alkaline phosphatase ≤ 2.5 x ULN
    • Serum creatinine \< 1.5 x ULN
  8. Patients must have the following electrolyte values ≥ LLN (lower limit of normal) limits or corrected to within normal limits with supplements prior to the first dose of study medication:

    • Potassium
    • Magnesium
    • Total calcium (corrected for serum albumin)
  9. Patients must have normal marrow function as defined below:

    • (ANC) ≥ 1.5 x 109/L
    • ≥ 100 x 109/L
    • ≥ 9.0 g/dL
  10. Written obtained prior to any screening procedures

Exclusion criteria

Exclusion Criteria:

  1. Prior AP, BC or allo-transplant
  2. Patient has documented MR4.5 at the time when switched from imatinib to nilotinib
  3. Patients with known atypical transcript
  4. CML treatment resistant mutation(s) (T315I, E255K/V, Y253H, F359C/V) detected if a testing was done in the past (there is no requirement to perform mutation testing at study entry if it was not done in the past)
  5. Dose reductions due to neutropenia or thrombocytopenia in the past 6 months
  6. Patient ever attempted to permanently discontinue imatinib or nilotinib treatment
  7. Known impaired cardiac function including any one of the following:

    • Inability to determine the on
    • Complete left bundle branch block
    • Long QT syndrome or a known family history of long QT syndrome
    • History of or presence of ventricular or atrial tachyarrhythmias
    • Clinically significant resting bradycardia
    • QTcF > 480 msec
    • History or clinical signs of myocardial infarction within 1 year prior to study entry
    • History of unstable angina within 1 year prior to study entry
    • Other clinically significant heart disease (e.g. uncontrolled congestive heart failure or uncontrolled hypertension)
  8. Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. uncontrolled diabetes (defined as > 9%), uncontrolled infection)
  9. History of acute pancreatitis within 1 year prior to study entry or past medical history of chronic pancreatitis
  10. Known presence of a significant congenital or acquired bleeding disorder unrelated to cancer
  11. History of other active within 5 years prior to study entry with the exception of previous or concomitant basal cell skin cancer, previous cervical carcinoma in situ treated curatively
  12. Patients who have not recovered from prior surgery
  13. Treatment with other agents (defined as not used in accordance with the approved indication) within 4 weeks of Day 1
  14. Patients actively receiving therapy with strong inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to study entry. See Appendix 14.1 for a list of these medications. This list may not be comprehensive.
  15. Patients actively receiving therapy with herbal medicines that are strong CYP3A4 inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to study entry. These herbal medicines may include Echinacea, (including E. purpurea, E. angustifolia and E. pallida), Piperine, Artemisinin, St. John's Wort, and Ginkgo.
  16. Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either safely discontinued or switched to a different medication prior to study entry. (Please see www.azcert.org/medical-pros/drug-lists/printable-drug-list.cfm for a list of agents that prolong the QT interval.)
  17. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery)
  18. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
  19. Women of , defined as all women physiologically capable of becoming pregnant, must have a negative serum pregnancy test before initiation of study treatment and must also use highly effective methods of while enrolled in the study. The use of highly effective contraception should continue for at least 14 days after the last dose of study treatment or until the last day of TFR/TFR-2, or for the duration of a monthly cycle of oral contraception, whichever is longer. Acceptable forms of highly effective contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
    • Male sterilization (at least 6 months prior to screening). The vasectomized male partner should be the sole partner for that subject Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception, women should be stable on the same pill for a minimum of 3 months before taking study treatment. Women are considered and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks prior to enrolling. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential. If a study patient becomes pregnant or is suspected of being pregnant during the study or within 30 days as part of safety evaluations after the final dose of nilotinib, the Study Doctor needs to be informed immediately and any ongoing study treatment with nilotinib has to be stopped immediately.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
163 participants (actual)

Study arms

  • Experimental
    Nilotinib

    Patients with minimum 3 years of tyrosine kinase inhibitor treatment (first with imatinib and then switched to nilotinib) since initial diagnosis, at least 2 years of nilotinib treatment prior to study entry and who achieved MR4.5 (local laboratory assessment) during nilotinib treatment, and determined by a Novartis designated central PCR lab assessment at screening

    Drug: nilotinib

Interventions

  • Nilotinib was dosed by weight or body surface area. Nilotinib 300 mg BID or 400 mg BID was be administered orally at approximately 12 hour intervals, and must not have been taken with food. The capsules were to be swallowed whole with water. No food should have been consumed for at least 2 hours before the dose was taken and no additional food should have been consumed for at least one hour after the dose was taken. Patients were also allowed to enter this study on the same dose they were taking prior to study entry. Patients who required permanent dose reduction from their original starting dose were to be allowed to enter this study on the same dose only if the patient maintained this dose for a minimum of 6 months prior to study entry.

    Also known as: AMN107

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in TFR Within 48-weeks Following Nilotinib Cessation

    TFR is defined as no confirmed loss of MR4 (Molecular response 4.0 log reduction from baseline) or loss of MMR (major molecular response) and no re-starting of nilotinib therapy within 12 months following cessation of nilotinib. Confirmed loss of MR4 is two consecutive BCR-ABL \> 0.01% IS. Loss of MMR does not require confirmation.

    Time frame: first 48 weeks following nilotinib cessation

Secondary outcomes

  1. Percentage of Participants in TFR Within 96, 144, 192, 264 Weeks, and Within the End of Years 6, 7, 8, 9 and 10 Following Nilotinib Cessation

    TFR is defined as no confirmed loss of MR4 (molecular response 4.0 log reduction from baseline) or loss of MMR (major molecular response) and no re-starting of nilotinib therapy within 12 months following cessation of nilotinib. Confirmed loss of MR4 is two consecutive BCR-ABL \> 0.01% IS. Loss of MMR does not require confirmation.

    Time frame: first 96, 144, 192, 264 weeks, and within the end of years 6, 7, 8, 9 and 10 following nilotinib cessation.

  2. Progression Free Survival (PFS) After the Start of the TFR Phase

    Progression free survival, defined as the time from the date of start of TFR to the date of event defined as the first occurrence of documented disease progression to Accelerated phase/Blast Crises (AP/BC) or the date of death from any cause.

    Time frame: nilotinib cessation up to approximately 580 weeks

  3. Treatment Free Survival (TFS) After the Start of the TFR Phase

    Treatment-free survival defined as the time from the date of start of TFR to the date of earliest occurrence of any of the following events: loss of MMR, confirmed loss of MR4, re-initiation of nilotinib treatment due to any cause, progression to acute phase (AP) or blast crisis (BC) or death due to any cause.

    Time frame: nilotinib cessation up to approximately 580 weeks

  4. Overall Survival (OS) After the Start of the TFR Phase

    Overall survival, defined as the time from start date of TFR (date of entering the TFR phase) to date of death due to any cause at any time during the study, including the follow-up period after discontinuation of study up to LPLV. If a patient is not known to have died, survival will be censored at the date of last contact.

    Time frame: nilotinib cessation up to approximately 580 weeks

  5. BCR-ABL Ratio (%) Over Time in Nilotinib Treatment Re-initiation Phase (NTRI)

    ABL= Abelson leukemia virus and BCR=Break point cluster region. The BCR-ABL ratio (%) represents the level of BCR-ABL fusion gene transcripts relative to a control gene (ABL) measured in peripheral blood samples using quantitative reverse transcription polymerase chain reaction (RT-PCR). Results are expressed as a percentage on the International Scale (IS), a standardized reporting method that allows comparison across laboratories. The BCR-ABL ratio is used to assess the molecular response to treatment, with lower values indicating a reduced disease burden.

    Time frame: re-start of nilotinib up to approximately 48 weeks

  6. Percentage of Participants With Stable MMR in Nilotinib Re-initiation Phase

    Percentage of participants who were in stable MMR (stable MMR=BCR-ABL ≤ 0.1% IS) at multiple timepoints after achievement of that response in the nilotinib re-initiation phase for those timepoints.

    Time frame: at 48 weeks, 96 weeks, 144 weeks, 192 weeks, 240 weeks, 288 weeks, 336 weeks, 384 weeks and 432 weeks after re-initiating Nilotinib in the NTRI Phase

  7. Proportion of Participants With Stable MR4.5 in Nilotinib Re-initiation Phase

    Percentage of participants who were in stable MR4.5 (stable MR4.5=BCR-ABL ≤ 0.0032% IS) at multiple time points after achievement of that response in the nilotinib re-initiation phase for those timepoints.

    Time frame: at 48 weeks, 96 weeks, 144 weeks, 192 weeks, 240 weeks, 288 weeks, 336 weeks, 384 weeks and 432 weeks

  8. Percentage of Participants With Stable MR4 in Nilotinib Re-initiation Phase

    Percentage of participants who were in stable MR4 (stable MR4=BCR-ABL ≤ 0.01% IS) at multiple timepoints after achievement of that response in the nilotinib re-initiation phase for those timepoints.

    Time frame: at 48 weeks, 96 weeks, 144 weeks, 192 weeks, 240 weeks, 288 weeks, 336 weeks, 384 weeks and 432 weeks

07

Results

Posted Jan 13, 2021

Participant flow

Recruitment for the study comprised a total of 163 participants, who were enrolled at 63 clinical sites distributed across 18 different countries.. Argentina (2), Australia (3), Belgium (1), Brazil (6), Canada (4), France (5), Germany (5), Greece (3), Israel (3), Japan (7), Mexico (1), Poland (3), Russia (3), Singapore (1), South Korea (1), Spain (8), UK (2), US (5)

Participant flow — Overall Study
MilestoneNTCS Phase
Started163
Tfr phase126
Ntri phase61
Ntct phase26
Tfr-2 phase7
Ntri-2 phase2
Ntct-p phase14
Completed152
Not completed11
Withdrew: Adverse event5
Withdrew: Physician decision1
Withdrew: Pregnancy1
Withdrew: Protocol violation1
Withdrew: Subject/guardian decision2
Withdrew: Death1

Outcome measures

PrimaryPercentage of Participants in TFR Within 48-weeks Following Nilotinib Cessation

TFR is defined as no confirmed loss of MR4 (Molecular response 4.0 log reduction from baseline) or loss of MMR (major molecular response) and no re-starting of nilotinib therapy within 12 months following cessation of nilotinib. Confirmed loss of MR4 is two consecutive BCR-ABL \> 0.01% IS. Loss of MMR does not require confirmation.

Time frame:
first 48 weeks following nilotinib cessation
Reported as:
Count of participants · Participants
Percentage of Participants in TFR Within 48-weeks Following Nilotinib Cessation
ParticipantsTFR Phase
Percentage of Participants in TFR Within 48-weeks Following Nilotinib Cessation73
SecondaryPercentage of Participants in TFR Within 96, 144, 192, 264 Weeks, and Within the End of Years 6, 7, 8, 9 and 10 Following Nilotinib Cessation

TFR is defined as no confirmed loss of MR4 (molecular response 4.0 log reduction from baseline) or loss of MMR (major molecular response) and no re-starting of nilotinib therapy within 12 months following cessation of nilotinib. Confirmed loss of MR4 is two consecutive BCR-ABL \> 0.01% IS. Loss of MMR does not require confirmation.

Time frame:
first 96, 144, 192, 264 weeks, and within the end of years 6, 7, 8, 9 and 10 following nilotinib cessation.
Reported as:
Count of participants · Participants
Percentage of Participants in TFR Within 96, 144, 192, 264 Weeks, and Within the End of Years 6, 7, 8, 9 and 10 Following Nilotinib Cessation
ParticipantsTFR Phase
Week 9667
Week 14461
Week 19258
Week 26454
Week 31250
Week 36044
Week 40841
Week 46838
Week 52832
SecondaryProgression Free Survival (PFS) After the Start of the TFR Phase

Progression free survival, defined as the time from the date of start of TFR to the date of event defined as the first occurrence of documented disease progression to Accelerated phase/Blast Crises (AP/BC) or the date of death from any cause.

Time frame:
nilotinib cessation up to approximately 580 weeks
Reported as:
Median · Weeks
Progression Free Survival (PFS) After the Start of the TFR Phase
WeeksTFR Phase
Progression Free Survival (PFS) After the Start of the TFR PhaseNA (NA to NA)
SecondaryTreatment Free Survival (TFS) After the Start of the TFR Phase

Treatment-free survival defined as the time from the date of start of TFR to the date of earliest occurrence of any of the following events: loss of MMR, confirmed loss of MR4, re-initiation of nilotinib treatment due to any cause, progression to acute phase (AP) or blast crisis (BC) or death due to any cause.

Time frame:
nilotinib cessation up to approximately 580 weeks
Reported as:
Median · Weeks
Treatment Free Survival (TFS) After the Start of the TFR Phase
WeeksTFS Phase
Treatment Free Survival (TFS) After the Start of the TFR Phase169 (27.9 to NA)
SecondaryOverall Survival (OS) After the Start of the TFR Phase

Overall survival, defined as the time from start date of TFR (date of entering the TFR phase) to date of death due to any cause at any time during the study, including the follow-up period after discontinuation of study up to LPLV. If a patient is not known to have died, survival will be censored at the date of last contact.

Time frame:
nilotinib cessation up to approximately 580 weeks
Reported as:
Median · Weeks
Overall Survival (OS) After the Start of the TFR Phase
WeeksTFS Phase
Overall Survival (OS) After the Start of the TFR PhaseNA (NA to NA)
SecondaryBCR-ABL Ratio (%) Over Time in Nilotinib Treatment Re-initiation Phase (NTRI)

ABL= Abelson leukemia virus and BCR=Break point cluster region. The BCR-ABL ratio (%) represents the level of BCR-ABL fusion gene transcripts relative to a control gene (ABL) measured in peripheral blood samples using quantitative reverse transcription polymerase chain reaction (RT-PCR). Results are expressed as a percentage on the International Scale (IS), a standardized reporting method that allows comparison across laboratories. The BCR-ABL ratio is used to assess the molecular response to treatment, with lower values indicating a reduced disease burden.

Time frame:
re-start of nilotinib up to approximately 48 weeks
Reported as:
Mean · Percent
BCR-ABL Ratio (%) Over Time in Nilotinib Treatment Re-initiation Phase (NTRI)
PercentNTRI Phase
Baseline1.53342 ± 8.070454
Week 41.01436 ± 4.354164
Week 80.44840 ± 2.571063
Week 120.29952 ± 2.232066
Week 160.33012 ± 2.481822
Week 200.18411 ± 1.330561
Week 240.00377 ± 0.013461
Week 360.01599 ± 0.106080
Week 480.02040 ± 0.132190
SecondaryPercentage of Participants With Stable MMR in Nilotinib Re-initiation Phase

Percentage of participants who were in stable MMR (stable MMR=BCR-ABL ≤ 0.1% IS) at multiple timepoints after achievement of that response in the nilotinib re-initiation phase for those timepoints.

Time frame:
at 48 weeks, 96 weeks, 144 weeks, 192 weeks, 240 weeks, 288 weeks, 336 weeks, 384 weeks and 432 weeks after re-initiating Nilotinib in the NTRI Phase
Reported as:
Count of participants · Participants
Percentage of Participants With Stable MMR in Nilotinib Re-initiation Phase
ParticipantsNTRI Phase
Stable MMR for 48 weeks52
Stable MMR for 96 weeks46
Stable MMR for 144 weeks41
Stable MMR for 192 weeks38
Stable MMR for 240 weeks31
Stable MMR for 288 weeks27
Stable MMR for 336 weeks24
Stable MMR for 384 weeks22
Stable MMR for 432 weeks [18
SecondaryProportion of Participants With Stable MR4.5 in Nilotinib Re-initiation Phase

Percentage of participants who were in stable MR4.5 (stable MR4.5=BCR-ABL ≤ 0.0032% IS) at multiple time points after achievement of that response in the nilotinib re-initiation phase for those timepoints.

Time frame:
at 48 weeks, 96 weeks, 144 weeks, 192 weeks, 240 weeks, 288 weeks, 336 weeks, 384 weeks and 432 weeks
Reported as:
Count of participants · Participants
Proportion of Participants With Stable MR4.5 in Nilotinib Re-initiation Phase
ParticipantsNTRI Phase
Stable MR4.5 for 48 weeks46
Stable MR4.5 for 96 weeks43
Stable MR4.5 for 144 weeks39
Stable MR4.5 for 192 weeks35
Stable MR4.5 for 240 weeks29
Stable MR4.5 for 288 weeks25
Stable MR4.5 for 336 weeks23
Stable MR4.5 for 384 weeks21
Stable MR4.5 for 432 weeks18
SecondaryPercentage of Participants With Stable MR4 in Nilotinib Re-initiation Phase

Percentage of participants who were in stable MR4 (stable MR4=BCR-ABL ≤ 0.01% IS) at multiple timepoints after achievement of that response in the nilotinib re-initiation phase for those timepoints.

Time frame:
at 48 weeks, 96 weeks, 144 weeks, 192 weeks, 240 weeks, 288 weeks, 336 weeks, 384 weeks and 432 weeks
Reported as:
Count of participants · Participants
Percentage of Participants With Stable MR4 in Nilotinib Re-initiation Phase
ParticipantsNTRI Phase
Stable MR4 for 48 weeks48
Stable MR4 for 96 weeks44
Stable MR4 for 144 weeks40
Stable MR4 for 192 weeks36
Stable MR4 for 240 weeks30
Stable MR4 for 288 weeks26
Stable MR4 for 336 weeks23
Stable MR4 for 384 weeks21
Stable MR4 for 432 weeks18

Adverse events

Collected over Adverse events were monitored/assessed for the following duration for each phase: NTCS: up to 52 weeks, TFR Phase: up to 528 weeks, NTRI Phase: up to 500 weeks, NTCT Phase: up to 48 weeks, TFR-2 Phase: up to 480 weeks, NTRI-2 Phase: up to 460 weeks, NTCT-P Phase: up to 480 weeks; Post-treatment follow up (only deaths monitored/assessed): up to 1 year after end of participation in the study phases.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nilotinib Treatment Consolidation (NTCS) Phase1/163 (0.6%)21/163 (12.9%)103/163 (63.2%)
Nilotinib Treatment-free Remission (TFR) Phase3/126 (2.4%)34/126 (27%)93/126 (73.8%)
Nilotinib Treatment Re-initiation (NTRI) Phase1/61 (1.6%)27/61 (44.3%)56/61 (91.8%)
Nilotinib Treatment Continuation (NTCT) Phase0/26 (0%)3/26 (11.5%)19/26 (73.1%)
Nilotinib Treatment-free Remission - 2 Phase (TRF-2)0/7 (0%)3/7 (42.9%)6/7 (85.7%)
Nilotinib Treatment Re-initiation-2 Phase (NTRI-2)0/2 (0%)2/2 (100%)2/2 (100%)
Nilotinib Treatment Prolonged Continuation Phase (NTCT-P)0/14 (0%)5/14 (35.7%)11/14 (78.6%)
All Patients5/163 (3.1%)80/163 (49.1%)151/163 (92.6%)
Post-treatment Follow-up7/71 (9.9%)——
Most frequent serious events
Showing 10 of 136
Most frequent serious events
EventNilotinib Treatment Consolidation (NTCS) PhaseNilotinib Treatment-free Remission (TFR) PhaseNilotinib Treatment Re-initiation (NTRI) PhaseNilotinib Treatment Continuation (NTCT) PhaseNilotinib Treatment-free Remission - 2 Phase (TRF-2)Nilotinib Treatment Re-initiation-2 Phase (NTRI-2)Nilotinib Treatment Prolonged Continuation Phase (NTCT-P)All PatientsPost-treatment Follow-up
Cardiovascular disorderCardiac disorders0/1630/1260/610/260/71/20/141/163—
Arterial occlusive diseaseVascular disorders0/1630/1260/610/260/71/20/141/163—
Inguinal herniaGastrointestinal disorders0/1632/1260/610/261/70/20/143/163—
Oedema peripheralGeneral disorders0/1630/1260/610/261/70/20/141/163—
Hepatic encephalopathyNervous system disorders0/1630/1260/610/261/70/20/141/163—
Duodenal ulcer perforationGastrointestinal disorders0/1630/1260/610/260/70/21/141/163—
Urinary tract infectionInfections and infestations0/1631/1260/610/260/70/21/142/163—
Spinal stenosisMusculoskeletal and connective tissue disorders0/1630/1261/610/260/70/21/142/163—
Thrombotic strokeNervous system disorders0/1630/1260/610/260/70/21/141/163—
IgA nephropathyRenal and urinary disorders0/1630/1260/610/260/70/21/141/163—
Most frequent other events
Showing 10 of 138
Most frequent other events
EventNilotinib Treatment Consolidation (NTCS) PhaseNilotinib Treatment-free Remission (TFR) PhaseNilotinib Treatment Re-initiation (NTRI) PhaseNilotinib Treatment Continuation (NTCT) PhaseNilotinib Treatment-free Remission - 2 Phase (TRF-2)Nilotinib Treatment Re-initiation-2 Phase (NTRI-2)Nilotinib Treatment Prolonged Continuation Phase (NTCT-P)All PatientsPost-treatment Follow-up
Staphylococcal infectionInfections and infestations0/1630/1260/610/260/71/20/141/163—
Procedural painInjury, poisoning and procedural complications0/1631/1262/610/261/71/20/145/163—
HyperglycaemiaMetabolism and nutrition disorders1/1635/12611/611/261/71/21/1418/163—
HypertriglyceridaemiaMetabolism and nutrition disorders1/1632/1266/610/262/71/21/1410/163—
HypervolaemiaMetabolism and nutrition disorders0/1630/1260/610/260/71/20/141/163—
AngiopathyVascular disorders0/1630/1260/610/260/71/20/141/163—
ArthralgiaMusculoskeletal and connective tissue disorders9/16343/12612/612/260/70/21/1462/163—
HypertensionVascular disorders13/16323/12619/611/261/70/22/1450/163—
COVID-19Infections and infestations0/16311/1264/610/261/70/24/1420/163—
MyalgiaMusculoskeletal and connective tissue disorders4/16322/1264/610/262/70/21/1432/163—

Baseline characteristics

Age, Continuous
Age, Continuous(years)NTCS Phase
Mean54.3 ± 13.99
Sex: Female, Male
Sex: Female, Male(Participants)NTCS Phase
Female86
Male77
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)NTCS Phase
Caucasian127
Black6
Asian23
Native American1
Other6
08

Study locations

62 sites
  • USC Kenneth Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Indiana Blood and Marrow Institute
    Beech Grove, Indiana 46107, United States
  • St Agnes Hospital
    Baltimore, Maryland 21229, United States
  • University of Texas Medical Branch
    Galveston, Texas 77555-0144, United States
  • Compass Oncology
    Vancouver, Washington 98683, United States
  • Novartis Investigative Site
    CABA, Buenos Aires C1221ADC, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1114AAN, Argentina
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    Box Hill, Victoria 3128, Australia
  • Novartis Investigative Site
    Antwerp, 2060, Belgium
  • Novartis Investigative Site
    Goiânia, Goiás 74605-050, Brazil
  • Novartis Investigative Site
    Belo Horizonte, Minas Gerais 30130-100, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, Rio de Janeiro 20211-030, Brazil
  • Novartis Investigative Site
    Rio de Janiero, Rio de Janeiro 20231-050, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90035-003, Brazil
  • Novartis Investigative Site
    Campinas, São Paulo 13083-970, Brazil
  • Novartis Investigative Site
    Hamilton, Ontario L8V 5C2, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Montreal, Quebec H1T 2M4, Canada
  • Novartis Investigative Site
    Québec, Quebec G1J 1Z4, Canada
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Grenoble, 38043, France
  • Novartis Investigative Site
    Lyon, 69373, France
  • Novartis Investigative Site
    Strasbourg, 67085, France
  • Novartis Investigative Site
    Vandœuvre-lès-Nancy, 54511, France
  • Novartis Investigative Site
    Mannheim, Baden-Wurttemberg 68305, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Heilbronn, 74072, Germany
  • Novartis Investigative Site
    Potsdam, 14467, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Athens, 106 76, Greece
  • Novartis Investigative Site
    Athens, 185 47, Greece
  • Novartis Investigative Site
    Larissa, 411 10, Greece
  • Novartis Investigative Site
    Haifa, 3109601, Israel
  • Novartis Investigative Site
    Petah Tikva, 4941492, Israel
  • Novartis Investigative Site
    Ramat Gan, 5265601, Israel
  • Novartis Investigative Site
    Nagoya, Aichi-ken 4648681, Japan
  • Novartis Investigative Site
    Narita, Chiba 286-8523, Japan
  • Novartis Investigative Site
    Kurume, Fukuoka 830-0011, Japan
  • Novartis Investigative Site
    Akita, 0108543, Japan
  • Novartis Investigative Site
    Aomori, 0308553, Japan
  • Novartis Investigative Site
    Chiba, 2608677, Japan
  • Novartis Investigative Site
    Fukuoka, 8128582, Japan
  • Novartis Investigative Site
    Monterrey, Nuevo León 64718, Mexico
  • Novartis Investigative Site
    Krakow, Lesser Poland Voivodeship 30-727, Poland
  • Novartis Investigative Site
    Gdansk, 80-952, Poland
  • Novartis Investigative Site
    Warsaw, 00-791, Poland
  • Novartis Investigative Site
    Moscow, 125167, Russia
  • Novartis Investigative Site
    Saint Petersburg, 191024, Russia
  • Novartis Investigative Site
    Saint Petersburg, 197341, Russia
  • Novartis Investigative Site
    Singapore, 169608, Singapore
  • Novartis Investigative Site
    Seoul, 06591, South Korea
  • Novartis Investigative Site
    Badalona, Barcelona 08916, Spain
  • Novartis Investigative Site
    Santander, Cantabria 39008, Spain
  • Novartis Investigative Site
    San Cristóbal de La Laguna, Santa Cruz De Tenerife 38320, Spain
  • Novartis Investigative Site
    Alicante, 03010, Spain
  • Novartis Investigative Site
    Madrid, 28006, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Madrid, 28046, Spain
  • Novartis Investigative Site
    Seville, 41013, Spain
  • Novartis Investigative Site
    Liverpool, L7 8XP, United Kingdom
  • Novartis Investigative Site
    Nottingham, NG5 1PB, United Kingdom
09

References and documents

Publications

  • Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, Ailawadhi S, Lipton JH, Turkina AG, De Paz R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Takahashi N, Fellague-Chebra R, Acharya S, Wong S, Jin Y, Hughes TP. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study. Ann Intern Med. 2018 Apr 3;168(7):461-470. doi: 10.7326/M17-1094. Epub 2018 Feb 20. PubMed 29459949 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2012 to primary completion in Nov 2015, 35 months.

Results were first posted in Jan 2021, 5 years 1 month after primary completion.

Of 25 industry-sponsored phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 69. This study's 35 months is below that.

Counting every sponsor, half of 126 studies reached it within 73 months; a quarter within 43 and three quarters within 124.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2012
First posted
Oct 3, 2012
StartActual
Dec 20, 2012
Primary completionActual
Nov 26, 2015
CompletionActual
Jan 29, 2025
Results first posted
Jan 13, 2021
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01698905
Responsible party
Sponsor
First posted
Oct 3, 2012
Start date
Dec 20, 2012
Primary completion
Nov 26, 2015
Completion
Jan 29, 2025
Results posted
Jan 13, 2021
Last update
Aug 12, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion